Industry

NEW YORK–(BUSINESS WIRE)–In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology. This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: … [Read more…]

MINNEAPOLIS–(BUSINESS WIRE)–Preceptis Medical, Inc., a commercial-stage medical technology company transforming pediatric ENT care, today announced the appointment of Dave Carey as Chief Executive Officer. Carey assumes leadership as the company accelerates toward full market release of its flagship product, the Hummingbird® Tympanostomy Tube System (TTS). “We are thrilled to welcome Dave Carey to Preceptis,” said … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–Avvio Medical Inc. today announced the publication of its AEROLITH randomized clinical trial in The Journal of Urology. Study highlights were presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic … [Read more…]

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex … [Read more…]

The Ngāi Tahu Research Centre coordinated project aims to advance ecological restoration and develop tools for conservation in Te Waipounamu, New Zealand’s South Island TE WAIPOUNAMU/SOUTH ISLAND, New Zealand–(BUSINESS WIRE)–In a historic indigenous-coordinated initiative, the Ngāi Tahu Research Centre has entered into a collaboration with Colossal Biosciences, a Texas-based genetic engineering and de-extinction company, and … [Read more…]

CHICAGO–(BUSINESS WIRE)–The SBB Research Group Foundation invited three prior grant recipients to share updates on their critical efforts to support the local community. The Foundation awarded additional grants to further each of the respective organizations’ missions (organizations listed alphabetically): Black Onyx Allstars (Chicago, IL) offers a culturally inclusive and empowering cheerleading experience that fosters community … [Read more…]

WELL continues to demonstrate strong momentum through continued organic and inorganic growth and is pleased to announce that it is ahead of internal expectations and has updated its guidance for its Canadian Patient Services segment to over $450 million(1) in revenue and over $60 million(1) in Adjusted EBITDA(2) for fiscal 2025. WELL’s Canadian Clinics business … [Read more…]

OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor diseases Phase 1/2a trial, CLARICO, is a first-in-human, multisite, 2-part interventional trial to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 Primary photoreceptor diseases are a subgroup of inherited retinal disorders that affect the structure … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–#invivoscribe–Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe’s global reference laboratories) have customized their multiparametric … [Read more…]

ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, helping eliminate cancer Already approved in the U.S. and designated as a Breakthrough Therapy by the FDA, this marks ANKTIVA’s first marketing approval outside the U.S. ANKTIVA plus BCG offers a new option for eligible patients … [Read more…]